Stay updated on Pembrolizumab and Olaparib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Olaparib in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Olaparib in NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page’s displayed UI/release revision changes from v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check25 days agoChange DetectedA new revision v3.5.2 was added and the previous revision v3.5.0 was removed.SummaryDifference0.0%

- Check54 days agoChange DetectedAdded revision v3.5.0 to the record history and removed revision v3.4.3.SummaryDifference0.0%

- Check61 days agoChange DetectedThe version history now shows an addition of Revision: v3.4.3 and removal of Revision: v3.4.2.SummaryDifference0.0%

- Check75 days agoChange DetectedStudy Status updated to Completed on 2026-02-25 and Recruitment Status updated accordingly, replacing the previous Active, not recruiting status.SummaryDifference0.2%

- Check90 days agoChange DetectedAn administrative update adds Revision: v3.4.2 to the history and removes the earlier funding/operating-status notice, reflecting system maintenance rather than study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab and Olaparib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Olaparib in NSCLC Clinical Trial page.